Pradaxa
Nuovi farmaci antitrombotici: che cosa cambierà in clinica nei prossimi anni? GF Gensini Livorno 27 marzo 2004.
An audit of the antithrombotic therapy for the management of valve repair or replacement Gellatly RM 1,2, Maydelmin D 1, Connell C 1, Marasco S 3, Zimmet.
ACC 2013 what did we learn
Stavros Apostolakis, MD, PhD University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; Antithrombotic therapy.
LE TRAITEMENT ANTITHROMBOTIQUE DE LA FA PROF L DE ROY UNIVERSITE DE LOUVAIN BELGIQUE.
I.V. Enoxaparin or Unfractionated Heparin in Primary PCI: Acute and Long-term results G. M ONTALESCOT, DISCLOSURE : Research Grants to the Institution.
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice.
Antiplatelet Therapy
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group 9 611 - 10/06/11.
Data Monitoring for Safety apparent harm with a new treatment ILLUMINATE trial
Disclosure Slide
